Methadone was found to significantly inhibit the in vitro and in vivo growth of human lung cancer cells. The in vitro growth inhibition (occurring at 1-100 nM methadone) was associated with changes in cell morphology and viability detectable within 1 hr and was irreversible after a 24-hr exposure to the drug. These effects of methadone could be reversed in the first 6 hr by naltrexone, actinomycin D, and cycloheximide, suggesting involvement of opioid-like receptors and the requirement for de novo mRNA and protein synthesis. The inhibitory effects of methadone on the growth of lung cancer cells also could be achieved by the less addictive (+) isomer of methadone. Characterization of the methadone binding to lung cancer cell membranes revealed high-affinity (nM), saturable binding sites for (±)-[3H]methadone, which crossreacted with ligands for ec, phencyclidine, or, but not jp, and 8 opioid receptors, and the binding characteristics appeared to be different from methadone sites present in rat brain. Methadone decreases cAMP levels in lung cancer cells, but the receptors are not coupled to a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. We conclude that the lung cancer growth inhibitory effects of methadone are significant, occur at low concentrations, and are mediated by a nonconventional type of opioid binding site distinct from methadone receptors found in the brain.
In addition to their use in the treatment of pain, opioids have been implicated in the regulation oftumor growth and biology (1) (2) (3) (4) (5) (6) (7) (8) . Recently, we have shown the presence of biologically active ,u, 8, and K membrane opioid receptors in human lung cancer lines of all histologic types. Opioid agonists selective for g, 8, and K ligands were shown to significantly inhibit the growth of these cells in culture (8) . In addition, (-)-nicotine reversed the growth inhibition by opioid agonists, suggesting a model in which the normal function of the endogenous opioid pathway would be to suppress tumor growth, while nicotine (from smoking) would overcome this suppressive effect (8) .
While examining various opioids for their potential therapeutic value in the treatment of lung cancer, we found the long-acting synthetic narcotic methadone, used for treatment of opioid addiction (9) (10) (11) , to be a very potent inhibitor of the in vitro and in vivo growth of human lung cancer cell lines. However, characterization of the methadone binding sites present on lung cancer cells revealed them to be distinct from other opioid receptors and from methadone binding sites present in rat brain membranes.
MATERIALS AND METHODS
Materials. (+)-[oo'-3H21Methadone (15.98 Ci/mmol; 1 Ci Cell Lines and Growth Assays. Small cell lung cancer (SCLC) and non-SCLC (adenocarcinoma, squamous, and large cell cancer) cell lines were grown in RPMI 1640 medium (GIBCO) supplemented with 10o fetal calf serum as described (12) (13) (14) . The calorimetric MTT assay was used to measure cell growth (8, 15) . Cell growth was also measured by counting viable cells in a hemocytometer by trypan blue dye exclusion after brief trypsinization and by a soft agarose colony formation assay (16) . For in vivo growth studies, 4-week-old athymic nude mice (N-Cr-nu; Harlan-SpragueDawley) were injected with 106 viable tumor cells (SCLC line NCI-N417) in 0.1 ml of medium into the right flank and tumors were allowed to grow to 3-5 mm diameter. Then, 0.1 ml of sterile saline (control) or methadone (10 mg per kg of body weight, in 0.1 ml of sterile saline solution) was given intraperitoneally daily for 20 days (10 mice per group). Alternatively, mice injected with NCI-H460 (non-SCLC) cells were treated with methadone or saline starting right after implantation (5 mice per group). Tumor diameters were measured daily.
Receptor Binding Assays. Cells were collected during the logarithmic phase of growth, membranes were prepared, and receptor binding assays were carried out as described (5, 8 (17) .
Intracellular cAMP Measurements. Cells were cultured for 4 days in 24-well plates in 2 ml of medium, and the medium was changed the day before drug treatment. The cells were incubated with the various drugs (100 nM) for 20 min (the time of maximal decrease in cAMP levels) at 37'C, extracts were prepared, and intracellular cAMP levels were measured by a radiometric assay (Amersham kit). Actinomycin D. Cell growth was significantly inhibited with only a few hours of methadone treatment (Fig. 4A) . After exposure for 4-6 hr to methadone, if the cells were washed and cultured in drug-free medium, subsequent growth of some lung cancer cells was seen, while no regrowth was seen after 24 hr exposure ( Fig. 1 G and H; Fig. 4A ). These results indicate that the continued presence of methadone is not essential for the growth inhibitory effect after the first few hours of treatment.
RESULTS AND DISCUSSION
Because of the need for only brief exposure to methadone to cause the loss of cell viability, we sought to determine whether de novo protein and mRNA synthesis were required for the methadone effect. Treatment of NCI-H157 cells with cycloheximide (5 Ag/ml) or actinomycin D (0.05 pug/ml), at concentrations that alone had little effect on trypan blue uptake (<10% trypan blue positive at 6 hr), was able to reverse the loss of cell viability caused by 1 ,uM methadone (82-99o trypan blue positive with methadone) during the first 6 hr of methadone treatment (Fig. 4B) . These results suggested that exposure to methadone results in de novo synthesis of mRNA and proteins that participate in the growth inhibitory effects of methadone.
Naltrexone Blocks Methadone Growth Inhibition. The longacting opioid antagonist naltrexone (100 nM) was able to retard the morphologic and cell viability effects of methadone (100 nM) on lung cancer cells during the first 6 hr of treatment, indicating that the methadone growth effects were mediated by opioid-like binding sites (Fig. 4C) . However, the inhibitory effect ofmethadone on growth eventually occurred after 24 hr of methadone exposure, even in the continued presence of naltrexone (data not shown). Further support for receptor mediation of the growth effects came from the finding that the inactive (+) isomer of naloxone was unable to reverse the morphologic and growth effects of methadone on lung cancer cells.
Methadone Causes a Decrease in Intracellular cAMP Levels.
A variety of properties characterize opioid receptors, including their ability to lower intracellular cAMP levels on activation, inhibition of opioid binding by the guanyl nucleotide GTP, and several protein-modifying agents (18 Opioids are known to lower intracellular cAMP levels through a pertussis toxin-sensitive guanine nucleotidebinding regulatory protein (18) . Thus, we tested whether pretreatment with pertussis toxin had any effect on methadone responses in lung cancer cells. In contrast to our previous results with morphine (8) , pretreatment of NCI-H187 cells with pertussis toxin for 3 hr before the addition of 100 nM methadone for 20 min did not reverse the decreases in intracellular cAMP levels observed with methadone alone (methadone treatment resulted in a 48% decrease in cAMP levels, while pertussis toxin pretreatment followed by methadone treatment resulted in a 51% decrease). Pertussis toxin at 100 ng/ml had no effect on the growth of lung cancer cells in vitro. While pertussis toxin (100 ng/ml) could effectively reverse the growth inhibitory effect of morphine (in NCI-N417 cells), it was unable to reverse methadone growth inhibition in either NCI-N417 or NCI-H157 cells as measured in the MTT assay (Fig. 4D) . Lung Cancer Cell Membranes Exhibit Specific Methadone Binding Sites. Even though methadone has been used clinically for many years, a review of the literature revealed no studies characterizing methadone binding sites in any cell type. Using membrane preparations from a variety of both (18, 20) . Similarly, we Proc. Nad. Acad. Sci. USA 89 (1992) found no stereospecificity for receptor binding to lung cancer cell membranes or the rat brain membranes, as both the (+) and (-) isomers of methadone could significantly displace (+)-[3H]methadone binding to these membranes (Table 1) .
Likewise, the growth effect was not stereospecific since both the (-) and (+) isomers of methadone were found to be equally potent in inhibiting the growth of the SCLC lines (NCI-H187, NCI-N417) and non-SCLC lines (NCI-H157 and NCI-H460) (data not shown). Both isomers of methadone also have been reported to reverse N-methyl-D-aspartate toxicity in cortical neurons (21) . Nicotine Is Unable to Reverse the Effects of Methadone on Lung Cancer Cells. We had previously shown (8) that nicotine was able to reverse the inhibitory effect of other opioids, like morphine, on the growth of lung cancer cells. However, in our current studies, nicotine at doses ranging from 10 nM and 1 ,uM was unable to significantly reverse the in vitro growthinhibitory action of methadone in a large number of the lung cancer cell lines. Likewise, nicotine had no effect on the binding of methadone to lung cancer cells and nicotine at 100 nM was not able to reverse the decrease in cAMP levels associated with methadone treatment (data not shown).
Methadone Has No Effects on Intracellular Calcium Levels. Some opioids act by directly modulating the voltage-sensitive calcium channels (18) . Using the Quin-2 technique (23), we were unable to measure changes in intracellular calcium levels over basal levels in these cells after addition of various doses of methadone (data not shown). In addition, the use of a calcium-channel blocker, Diltiazem, did not block the binding of methadone to its receptor, nor did it reverse the growth inhibitory effects of methadone, suggesting that modulation of calcium levels may not play a primary role in the action of methadone in these cells.
Conclusions. We have found that methadone, a drug already in wide clinical use, has significant growth inhibitory effects on lung cancer cells in vitro and in vivo, indicating that the antitumor effects of methadone should be investigated in patients. Our results suggest the intriguing possibility that the (+) isomer of methadone, with its lack of significant respiratory depressant activity and 10-fold lower binding to brain membranes than the (-) isomer (18, 20) , could be used to treat cancer, while potentially having less-addictive properties. In fact, if methadone is active in patients, its use could be considered at a very early stage of lung carcinogenesis in cigarette smokers. Previously, we found nicotine to reverse the growth inhibitory effects of morphine and DADLE ([DAla2,D-Leu5]enkephalin) in lung cancer cells (8) . In contrast, nicotine was unable to reverse the methadone effect in these cells, indicating the use of methadone instead of morphine in smokers for potentially preventing the development of lung cancer during its very early stages.
In studies using other cancer cell lines, we found that methadone caused the loss of viability in the trypan blue assay of two of two mesotheliomas, two of two colon cancers, two of two breast cancers, one T-cell lymphoma, and five of seven B-lymphoblastoid cell lines, indicating that methadone could be effective in inhibiting the growth ofother tumors in addition to lung cancer. However, several human tumor cell lines (especially the adrenal cortical carcinoma line NCI-H295) were resistant to methadone even at concentrations >5 gM. While the mechanism of methadone resistance in these lines is unknown, their existence demonstrates specificity at the cellular level of methadone growth inhibition.
It will be of great interest to characterize the methadone binding sites and to understand the mechanism of methadoneinduced growth inhibition in human cancer cells, as this could provide insight into ways to treat cancer. The need for only a brief exposure to methadone and the blocking of the effect with actinomycin D and cycloheximide suggest that methadone acts through a receptor by inducing the synthesis of proteins that participate in the cytotoxic effect. The molecular events that follow activation of the methadone receptor could involve changes in the expression of tumor suppressor or some other class of genes.
